Clinical Trial Update: A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating amivantamab added to standard of care versus standard of care alone in recurrent/metastatic head and neck squamous cell carcin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Amivantamab (amivantamab)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Squamous Cell Carcinoma of Head and Neck | Phase 3 | Status: RECRUITING